Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
Identifieur interne : 000171 ( PubMed/Corpus ); précédent : 000170; suivant : 000172Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
Auteurs : Lucie Hopes ; Guillaume Grolez ; Caroline Moreau ; Renaud Lopes ; Gilles Ryckewaert ; Nicolas Carrière ; Florent Auger ; Charlotte Laloux ; Maud Petrault ; Jean-Christophe Devedjian ; Regis Bordet ; Luc Defebvre ; Patrice Jissendi ; Christine Delmaire ; David DevosSource :
- PloS one [ 1932-6203 ] ; 2016.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Acute Disease, Aged, Animals, Biomarkers (analysis), Corpus Striatum (pathology), Cross-Sectional Studies, Female, Humans, Iron (analysis), Iron Overload (complications), Magnetic Resonance Imaging (methods), Male, Mice, Inbred C57BL, Middle Aged, Oxidative Stress, Parkinson Disease (complications), Parkinson Disease (pathology), Parkinson Disease, Secondary (complications), Parkinson Disease, Secondary (pathology), Substantia Nigra (pathology).
- MESH :
- chemical , analysis : Biomarkers, Iron.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- complications : Iron Overload, Parkinson Disease, Parkinson Disease, Secondary.
- methods : Magnetic Resonance Imaging.
- pathology : Corpus Striatum, Parkinson Disease, Parkinson Disease, Secondary, Substantia Nigra.
- Acute Disease, Aged, Animals, Cross-Sectional Studies, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Oxidative Stress.
Abstract
Magnetic resonance imaging (MRI) can be used to identify biomarkers in Parkinson's disease (PD); R2* values reflect iron content related to high levels of oxidative stress, whereas volume and/or shape changes reflect neuronal death. We sought to assess iron overload in the nigrostriatal system and characterize its relationship with focal and overall atrophy of the striatum in the pivotal stages of PD.
DOI: 10.1371/journal.pone.0147947
PubMed: 27035571
Links to Exploration step
pubmed:27035571Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?</title><author><name sortKey="Hopes, Lucie" sort="Hopes, Lucie" uniqKey="Hopes L" first="Lucie" last="Hopes">Lucie Hopes</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Grolez, Guillaume" sort="Grolez, Guillaume" uniqKey="Grolez G" first="Guillaume" last="Grolez">Guillaume Grolez</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lopes, Renaud" sort="Lopes, Renaud" uniqKey="Lopes R" first="Renaud" last="Lopes">Renaud Lopes</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ryckewaert, Gilles" sort="Ryckewaert, Gilles" uniqKey="Ryckewaert G" first="Gilles" last="Ryckewaert">Gilles Ryckewaert</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Carriere, Nicolas" sort="Carriere, Nicolas" uniqKey="Carriere N" first="Nicolas" last="Carrière">Nicolas Carrière</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Auger, Florent" sort="Auger, Florent" uniqKey="Auger F" first="Florent" last="Auger">Florent Auger</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Laloux, Charlotte" sort="Laloux, Charlotte" uniqKey="Laloux C" first="Charlotte" last="Laloux">Charlotte Laloux</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Petrault, Maud" sort="Petrault, Maud" uniqKey="Petrault M" first="Maud" last="Petrault">Maud Petrault</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Devedjian, Jean Christophe" sort="Devedjian, Jean Christophe" uniqKey="Devedjian J" first="Jean-Christophe" last="Devedjian">Jean-Christophe Devedjian</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jissendi, Patrice" sort="Jissendi, Patrice" uniqKey="Jissendi P" first="Patrice" last="Jissendi">Patrice Jissendi</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Delmaire, Christine" sort="Delmaire, Christine" uniqKey="Delmaire C" first="Christine" last="Delmaire">Christine Delmaire</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27035571</idno><idno type="pmid">27035571</idno><idno type="doi">10.1371/journal.pone.0147947</idno><idno type="wicri:Area/PubMed/Corpus">000171</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000171</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?</title><author><name sortKey="Hopes, Lucie" sort="Hopes, Lucie" uniqKey="Hopes L" first="Lucie" last="Hopes">Lucie Hopes</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Grolez, Guillaume" sort="Grolez, Guillaume" uniqKey="Grolez G" first="Guillaume" last="Grolez">Guillaume Grolez</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lopes, Renaud" sort="Lopes, Renaud" uniqKey="Lopes R" first="Renaud" last="Lopes">Renaud Lopes</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ryckewaert, Gilles" sort="Ryckewaert, Gilles" uniqKey="Ryckewaert G" first="Gilles" last="Ryckewaert">Gilles Ryckewaert</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Carriere, Nicolas" sort="Carriere, Nicolas" uniqKey="Carriere N" first="Nicolas" last="Carrière">Nicolas Carrière</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Auger, Florent" sort="Auger, Florent" uniqKey="Auger F" first="Florent" last="Auger">Florent Auger</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Laloux, Charlotte" sort="Laloux, Charlotte" uniqKey="Laloux C" first="Charlotte" last="Laloux">Charlotte Laloux</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Petrault, Maud" sort="Petrault, Maud" uniqKey="Petrault M" first="Maud" last="Petrault">Maud Petrault</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Devedjian, Jean Christophe" sort="Devedjian, Jean Christophe" uniqKey="Devedjian J" first="Jean-Christophe" last="Devedjian">Jean-Christophe Devedjian</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jissendi, Patrice" sort="Jissendi, Patrice" uniqKey="Jissendi P" first="Patrice" last="Jissendi">Patrice Jissendi</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Delmaire, Christine" sort="Delmaire, Christine" uniqKey="Delmaire C" first="Christine" last="Delmaire">Christine Delmaire</name><affiliation><nlm:affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation><nlm:affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Acute Disease</term><term>Aged</term><term>Animals</term><term>Biomarkers (analysis)</term><term>Corpus Striatum (pathology)</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Iron (analysis)</term><term>Iron Overload (complications)</term><term>Magnetic Resonance Imaging (methods)</term><term>Male</term><term>Mice, Inbred C57BL</term><term>Middle Aged</term><term>Oxidative Stress</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease, Secondary (complications)</term><term>Parkinson Disease, Secondary (pathology)</term><term>Substantia Nigra (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term><term>Iron</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Iron Overload</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Acute Disease</term><term>Aged</term><term>Animals</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Mice, Inbred C57BL</term><term>Middle Aged</term><term>Oxidative Stress</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Magnetic resonance imaging (MRI) can be used to identify biomarkers in Parkinson's disease (PD); R2* values reflect iron content related to high levels of oxidative stress, whereas volume and/or shape changes reflect neuronal death. We sought to assess iron overload in the nigrostriatal system and characterize its relationship with focal and overall atrophy of the striatum in the pivotal stages of PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27035571</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>02</Day></DateCreated><DateCompleted><Year>2016</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2016</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?</ArticleTitle><Pagination><MedlinePgn>e0147947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0147947</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Magnetic resonance imaging (MRI) can be used to identify biomarkers in Parkinson's disease (PD); R2* values reflect iron content related to high levels of oxidative stress, whereas volume and/or shape changes reflect neuronal death. We sought to assess iron overload in the nigrostriatal system and characterize its relationship with focal and overall atrophy of the striatum in the pivotal stages of PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty controls and 70 PD patients at different disease stages (untreated de novo patients, treated early-stage patients and advanced-stage patients with L-dopa-related motor complications) were included in the study. We determined the R2* values in the substantia nigra, putamen and caudate nucleus, together with striatal volume and shape analysis. We also measured R2* in an acute MPTP mouse model and in a longitudinal follow-up two years later in the early-stage PD patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The R2* values in the substantia nigra, putamen and caudate nucleus were significantly higher in de novo PD patients than in controls. Early-stage patients displayed significantly higher R2* values in the substantia nigra (with changes in striatal shape), relative to de novo patients. Measurements after a two-year follow-up in early-stage patients and characterization of the acute MPTP mouse model confirmed that R2* changed rapidly with disease progression. Advanced-stage patients displayed significant atrophy of striatum, relative to earlier disease stages.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Each pivotal stage in PD appears to be characterized by putative nigrostriatal MRI biomarkers: iron overload at the de novo stage, striatal shape changes at early-stage disease and generalized striatal atrophy at advanced disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hopes</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grolez</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroradiology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryckewaert</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrière</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auger</LastName><ForeName>Florent</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Small Animal Imaging Unit, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laloux</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Pharmacology, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrault</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Pharmacology, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devedjian</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Pharmacology, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordet</LastName><ForeName>Regis</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Pharmacology, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jissendi</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroradiology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmaire</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroradiology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Movement Disorders and Neurology, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1171, Faculty of Medicine, Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Pharmacology, Lille University, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Apr 30;25(6):687-95</RefSource><PMID Version="1">20437538</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Comput Assist Radiol Surg. 2013 Jan;8(1):99-110</RefSource><PMID Version="1">22426551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(3):e57904</RefSource><PMID Version="1">23469252</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Aging. 2013 Nov;34(11):2510-6</RefSource><PMID Version="1">23820588</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Dec;19(12):1136-42</RefSource><PMID Version="1">24025315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acad Radiol. 2014 Jan;21(1):64-71</RefSource><PMID Version="1">24331266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurol Sci. 2014 May;35(5):753-8</RefSource><PMID Version="1">24337946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2014 Jun;20(6):622-6</RefSource><PMID Version="1">24703894</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2014 Jun;29(7):897-903</RefSource><PMID Version="1">24817690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antioxid Redox Signal. 2014 Jul 10;21(2):195-210</RefSource><PMID Version="1">24251381</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2015 Jan 22;284:234-46</RefSource><PMID Version="1">25301748</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2003 Mar 27;37(6):899-909</RefSource><PMID Version="1">12670420</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1987 Nov 21;2(8569):1219-20</RefSource><PMID Version="1">2890848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Dementia. 1993 Mar-Apr;4(2):61-5</RefSource><PMID Version="1">8358514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 1993;39:165-72</RefSource><PMID Version="1">8360656</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1958 Oct;3(1):41-51</RefSource><PMID Version="1">13611557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosurgery. 2006 Feb;58(2):256-62; discussion 256-62</RefSource><PMID Version="1">16462479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJNR Am J Neuroradiol. 2007 Feb;28(2):309-13</RefSource><PMID Version="1">17297002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837</RefSource><PMID Version="1">17542011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Apr 15;70(16 Pt 2):1411-7</RefSource><PMID Version="1">18172063</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJNR Am J Neuroradiol. 2008 May;29(5):950-5</RefSource><PMID Version="1">18272561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Magn Reson Imaging. 2008 Nov;28(5):1061-7</RefSource><PMID Version="1">18972346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2010 Nov;133(11):3423-33</RefSource><PMID Version="1">20736190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Med Chem. 2011;18(12):1832-45</RefSource><PMID Version="1">21466469</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Aug 1;26(9):1627-32</RefSource><PMID Version="1">21618607</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2012 Feb;71(2):267-77</RefSource><PMID Version="1">22367998</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Res. 2012 May;65(5):514-22</RefSource><PMID Version="1">22391246</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019190" MajorTopicYN="N">Iron Overload</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4818028</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27035571</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0147947</ArticleId><ArticleId IdType="pii">PONE-D-15-28863</ArticleId><ArticleId IdType="pmc">PMC4818028</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000171 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000171 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27035571
|texte= Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27035571" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |